Carnegie Investment Bank Norway is proud to have acted as Joint Bookrunner in Targovax’ successful NOK 175 million rights issue.
The purpose of the rights issue is to provide the Company with runway into 3Q 2023, including the start of the next melanoma trial in second half of 2022, as well as the ongoing ONCOS and CMC trials, and pipeline extension.
Targovax is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. The company’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.
Carnegie congratulates CEO Erik Digman Wiklund, interim CFO Oystein Soug and the rest of the Targovax team with a successful transaction.